Population differences of study cohort vs excluded patients and clinical trial participants vs nonparticipants
| . | Excluded NHL lacking census tract (%) . | Total study cohort population . | P value (α = .05) . | Clinical Trial participants (%) . | Nonparticipants (%) . | P value (α = .05) . |
|---|---|---|---|---|---|---|
| n | 172 | 3146 | 950 (30.2) | 2196 (69.8) | ||
| Sex | ||||||
| Female | 74 (43) | 1274 (40.5) | .52 | 348 (36.6) | 926 (42.2) | .004 |
| Male | 98 (57) | 1872 (59.5) | 602 (63.4) | 1270 (57.8) | ||
| Age | ||||||
| Mean | 67 | 63 | <.0001 | 61 | 63 | .002 |
| SD | 11.1 | 14.6 | 14.2 | 14.7 | ||
| Median | 68 | 65 | 63 | 65 | ||
| Ethnicity | ||||||
| Hispanic/Latino | 25 (14.5) | 411 (13.1) | .90 | 110 (11.6) | 301 (13.7) | .12 |
| Non-Hispanic | 143 (83.1) | 2660 (84.6) | 822 (86.5) | 1838 (83.7) | ||
| Unknown | 4 (2.3) | 75 (2.4) | 18 (1.9) | 57 (2.6) | ||
| Race | ||||||
| NHW | 132 (76.7) | 2356 (74.9) | .40 | 742 (78.1) | 1614 (73) | .11 |
| Hispanic/Latino | 25 (14.5) | 411 (13.1) | 110 (11.6) | 301 (13.7) | ||
| Non-Hispanic Black/AA | 8 (4.7) | 189 (6) | 50 (5.3) | 139(6.3) | ||
| Non-Hispanic Asian | 2 (1.2) | 116 (3.7) | 29 (3.1) | 87 (3) | ||
| Other/unknown | 5 (2.9) | 74 (2.4) | 19 (2) | 55 (2.5) | ||
| Diagnosis | ||||||
| DLBCL | 55 (32) | 917 (29.1) | .89 | 259 (27.3) | 658 (30.0) | .0005 |
| FL | 41 (23.8) | 698 (22.2) | 154 (16.2) | 544 (24.8) | ||
| MCL | 18 (10.5) | 417 (13.3) | 228 (24) | 189 (8.6) | ||
| MZL | 16 (9.3) | 287(9.1) | 55 (5.8) | 214 (10.6) | ||
| TCL | 16 (9.3) | 259 (8.2) | 102 (10.7) | 157 (7.1) | ||
| Misc. | 12 (7) | 235 (7.5) | 49 (5.2) | 186 (8.5) | ||
| High-grade BCL | 8 (4.7) | 205 (6.5) | 63 (6.6) | 142 (6.5) | ||
| Composite | 6 (3.5) | 118 (3.8) | 39 (4.1) | 79 (3.6) | ||
| Gray zone lymphoma | 0 (0) | 10 (0.3) | 1 (0.1) | 9 (0.4) | ||
| Clinical trial type | ||||||
| Any | 50 (29.1) | 950 (30.2) | .95 | 950 (30.2) | N/A | |
| Noninterventional | 19 (11) | 403 (12.8) | .8 | 403 (12.8) | N/A | |
| Interventional, nontherapeutic | 3 (1.7) | 90 (2.9) | .69 | 90 (2.9) | N/A | |
| Interventional, therapeutic | 35 (20.3) | 646 (20.5) | .92 | 646 (20.5) | N/A | |
| Insurance type | ||||||
| Private insurance/managed care | 68 (39.5) | 1504 (47.8) | .011 | 472 (49.7) | 1032 (47) | .40 |
| Medicare | 101 (58.7) | 1452 (46.2) | 425 (44.7) | 1027 (46.8) | ||
| Medicaid | 0 (0) | 36 (1.1) | 11 (1.2) | 25 (1.1) | ||
| Self-pay | 0 (0) | 80 (2.5) | 18 (1.8) | 62 (2.8) | ||
| Government/other | 3 (1.7) | 74 (2.4) | 24 (2.5) | 50 (2.3) | ||
| ADI (quartiles) | n = 879 | n = 2009 | ||||
| Q1 (0-25) | N/A | N/A | N/A | 260 (29.6) | 514 (25.6) | .043 |
| Q2 (26-50) | N/A | N/A | 279 (31.7) | 610 (30.4) | ||
| Q3 (51-75) | N/A | N/A | 208 (23.7) | 545 (27.1) | ||
| Q4 (76-100) | N/A | N/A | 132 (15) | 340 (16.9) | ||
| ADI (Continuous) | ||||||
| Mean | N/A | N/A | N/A | 44 | 46 | 0.009 |
| SD | N/A | N/A | 26.1 | 26.2 | ||
| Median | N/A | N/A | 42 | 45 |
| . | Excluded NHL lacking census tract (%) . | Total study cohort population . | P value (α = .05) . | Clinical Trial participants (%) . | Nonparticipants (%) . | P value (α = .05) . |
|---|---|---|---|---|---|---|
| n | 172 | 3146 | 950 (30.2) | 2196 (69.8) | ||
| Sex | ||||||
| Female | 74 (43) | 1274 (40.5) | .52 | 348 (36.6) | 926 (42.2) | .004 |
| Male | 98 (57) | 1872 (59.5) | 602 (63.4) | 1270 (57.8) | ||
| Age | ||||||
| Mean | 67 | 63 | <.0001 | 61 | 63 | .002 |
| SD | 11.1 | 14.6 | 14.2 | 14.7 | ||
| Median | 68 | 65 | 63 | 65 | ||
| Ethnicity | ||||||
| Hispanic/Latino | 25 (14.5) | 411 (13.1) | .90 | 110 (11.6) | 301 (13.7) | .12 |
| Non-Hispanic | 143 (83.1) | 2660 (84.6) | 822 (86.5) | 1838 (83.7) | ||
| Unknown | 4 (2.3) | 75 (2.4) | 18 (1.9) | 57 (2.6) | ||
| Race | ||||||
| NHW | 132 (76.7) | 2356 (74.9) | .40 | 742 (78.1) | 1614 (73) | .11 |
| Hispanic/Latino | 25 (14.5) | 411 (13.1) | 110 (11.6) | 301 (13.7) | ||
| Non-Hispanic Black/AA | 8 (4.7) | 189 (6) | 50 (5.3) | 139(6.3) | ||
| Non-Hispanic Asian | 2 (1.2) | 116 (3.7) | 29 (3.1) | 87 (3) | ||
| Other/unknown | 5 (2.9) | 74 (2.4) | 19 (2) | 55 (2.5) | ||
| Diagnosis | ||||||
| DLBCL | 55 (32) | 917 (29.1) | .89 | 259 (27.3) | 658 (30.0) | .0005 |
| FL | 41 (23.8) | 698 (22.2) | 154 (16.2) | 544 (24.8) | ||
| MCL | 18 (10.5) | 417 (13.3) | 228 (24) | 189 (8.6) | ||
| MZL | 16 (9.3) | 287(9.1) | 55 (5.8) | 214 (10.6) | ||
| TCL | 16 (9.3) | 259 (8.2) | 102 (10.7) | 157 (7.1) | ||
| Misc. | 12 (7) | 235 (7.5) | 49 (5.2) | 186 (8.5) | ||
| High-grade BCL | 8 (4.7) | 205 (6.5) | 63 (6.6) | 142 (6.5) | ||
| Composite | 6 (3.5) | 118 (3.8) | 39 (4.1) | 79 (3.6) | ||
| Gray zone lymphoma | 0 (0) | 10 (0.3) | 1 (0.1) | 9 (0.4) | ||
| Clinical trial type | ||||||
| Any | 50 (29.1) | 950 (30.2) | .95 | 950 (30.2) | N/A | |
| Noninterventional | 19 (11) | 403 (12.8) | .8 | 403 (12.8) | N/A | |
| Interventional, nontherapeutic | 3 (1.7) | 90 (2.9) | .69 | 90 (2.9) | N/A | |
| Interventional, therapeutic | 35 (20.3) | 646 (20.5) | .92 | 646 (20.5) | N/A | |
| Insurance type | ||||||
| Private insurance/managed care | 68 (39.5) | 1504 (47.8) | .011 | 472 (49.7) | 1032 (47) | .40 |
| Medicare | 101 (58.7) | 1452 (46.2) | 425 (44.7) | 1027 (46.8) | ||
| Medicaid | 0 (0) | 36 (1.1) | 11 (1.2) | 25 (1.1) | ||
| Self-pay | 0 (0) | 80 (2.5) | 18 (1.8) | 62 (2.8) | ||
| Government/other | 3 (1.7) | 74 (2.4) | 24 (2.5) | 50 (2.3) | ||
| ADI (quartiles) | n = 879 | n = 2009 | ||||
| Q1 (0-25) | N/A | N/A | N/A | 260 (29.6) | 514 (25.6) | .043 |
| Q2 (26-50) | N/A | N/A | 279 (31.7) | 610 (30.4) | ||
| Q3 (51-75) | N/A | N/A | 208 (23.7) | 545 (27.1) | ||
| Q4 (76-100) | N/A | N/A | 132 (15) | 340 (16.9) | ||
| ADI (Continuous) | ||||||
| Mean | N/A | N/A | N/A | 44 | 46 | 0.009 |
| SD | N/A | N/A | 26.1 | 26.2 | ||
| Median | N/A | N/A | 42 | 45 |
Boldface values denote statistical significance at the P value < .05 level.
AA, African American; BCL, B-cell lymphoma; Misc., miscellaneous; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; N/A, not applicable; SD, standard deviation; TCL, T-cell lymphoma.